A clinical trial update dated July 23, 2026 reports that a study of plecanatide has moved to active, not recruiting status.
The trial, registered as NCT07723924, is a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. It is evaluating two weight-based treatment groups of plecanatide compared to placebo.
The study population includes children and adolescent participants aged 6 to less than 18 years with functional constipation. It is currently listed as Phase 2.
The update indicates the trial's status as active, not recruiting, meaning enrollment has closed but the study is ongoing. No results have been posted as part of this update.
Plecanatide is an approved compound, and this trial concerns its investigation in a pediatric population for functional constipation. The listing does not include efficacy or safety outcomes at this stage.
Further details about the trial design and status are available through the official registration record. Readers can find more context on plecanatide in the compound overview.